Sanuwave Health Reports Preliminary Q1 2026 Revenue Up 3-4% Year-over-Year

The medical device company expects Q1 revenue between $9.6-$9.7 million despite market challenges.

Apr. 16, 2026 at 10:23pm

Got story updates? Submit your updates here. ›

A close-up photograph of a polished metal medical device with clean geometric shapes, illuminated by dramatic studio lighting against a solid white background, conceptually representing innovation and strategy in the medical technology industry.A sleek, high-tech medical device symbolizes Sanuwave's innovative approach to advanced wound care amid a shifting market landscape.Eden Prairie Today

Sanuwave Health, a provider of FDA-approved directed energy systems for advanced wound care, announced preliminary Q1 2026 revenue in the range of $9.6 to $9.7 million, an increase of 3-4% over the same period last year. The company said Q1 revenue was impacted by some deals sliding out of the quarter, as well as changes in reimbursement for certain wound care products that caused market participants to pause activities. However, Sanuwave remains optimistic about the future, noting strong interest from practitioners at a recent industry conference.

Why it matters

Sanuwave's preliminary Q1 results provide an early look at the company's performance amid ongoing shifts in the advanced wound care market. While the company faced some headwinds in the quarter, its ability to still deliver year-over-year growth and maintain optimism about the future suggests Sanuwave may be well-positioned to navigate the changing landscape.

The details

Sanuwave said several large deals it expected to close in Q1 2026 were pushed out of the quarter, bringing revenue toward the lower end of its guidance range. The company also cited changes in reimbursement for skin substitutes and allografts that caused 'many market participants and practitioners to pause or pull back from their activities in advanced wound care.' However, Sanuwave said it saw strong interest from practitioners at a recent industry conference, with its booth and workshops drawing high attendance as customers looked for 'options going forward.' The company said it plans to 'lean in' and believes its Ultramist technology can be an important part of the 'forward roadmap for patient care' in the wound care space.

  • Sanuwave reported preliminary Q1 2026 revenue on April 16, 2026.
  • The company's Q4 2025 earnings release was issued on March 26, 2026.

The players

Sanuwave Health, Inc.

A leading provider of FDA-approved directed energy systems used in advanced wound care.

Morgan Frank

CEO of Sanuwave Health.

Got photos? Submit your photos here. ›

What they’re saying

“At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in toward the lower end of our guidance range.”

— Morgan Frank, CEO

“Q1 has been a sort of reckoning in the wound care space as practitioners and customers came to terms with some significant changes in reimbursement for skin substitutes and allografts and this has caused many market participants and practitioners to pause or pull back from their activities in advanced wound care.”

— Morgan Frank, CEO

“But, as we discussed on our Q4 call, the patients and the wounds have not gone away and the need for care remains. At the SAWC conference in Charlotte last week, we spoke to a great many practitioners who were asking 'So what now?' and looking for options going forward. Our booth was as busy as any of us can ever recall seeing it, our hands-on workshops were full, and interest was high.”

— Morgan Frank, CEO

“For these reasons, we're not pulling back but rather leaning in as we believe that Ultramist can be an important part of the forward roadmap for patient care. I'm not sure we can quite say 'the tide has fully turned' at this point, but, at the very least, it does seem like perhaps the turn is starting and our optimism is increasing.”

— Morgan Frank, CEO

What’s next

Sanuwave plans to report its full Q1 2026 financial results in May.

The takeaway

Sanuwave's preliminary Q1 results show the company is navigating a challenging period in the advanced wound care market, but remains optimistic about its ability to provide solutions that meet the ongoing needs of practitioners and patients. The company's focus on innovation and customer engagement suggests it is well-positioned to adapt to the evolving landscape.